Leerink Partnrs Issues Negative Outlook for ELAN Earnings

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Leerink Partnrs cut their Q1 2025 earnings per share estimates for shares of Elanco Animal Health in a report issued on Monday, April 21st. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings of $0.28 per share for the quarter, down from their previous forecast of $0.29. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health's Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.78 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $1.09 EPS and FY2028 earnings at $1.29 EPS.

ELAN has been the topic of a number of other research reports. Piper Sandler lowered their price objective on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Barclays decreased their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Stifel Nicolaus reduced their target price on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a report on Monday, April 14th. UBS Group lowered their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Finally, Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $14.67.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN traded down $0.03 during midday trading on Wednesday, hitting $9.44. The stock had a trading volume of 1,332,753 shares, compared to its average volume of 4,919,042. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock has a 50 day moving average price of $10.03 and a two-hundred day moving average price of $11.62. The company has a market capitalization of $4.68 billion, a PE ratio of 23.62, a P/E/G ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the firm posted $0.08 EPS. The company's revenue for the quarter was down 1.4% on a year-over-year basis.

Insider Transactions at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was purchased at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.89% of the company's stock.

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds have recently modified their holdings of the company. Steward Partners Investment Advisory LLC lifted its stake in shares of Elanco Animal Health by 28.3% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock valued at $124,000 after buying an additional 2,264 shares during the period. DDD Partners LLC purchased a new stake in shares of Elanco Animal Health in the fourth quarter valued at $5,974,000. Harbor Capital Advisors Inc. increased its stake in Elanco Animal Health by 24.0% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company's stock valued at $13,135,000 after purchasing an additional 209,734 shares during the last quarter. Franklin Resources Inc. lifted its position in Elanco Animal Health by 14.0% during the third quarter. Franklin Resources Inc. now owns 372,230 shares of the company's stock worth $5,349,000 after buying an additional 45,795 shares during the period. Finally, Jones Financial Companies Lllp boosted its stake in Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after buying an additional 2,059 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.